<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00642174</url>
  </required_header>
  <id_info>
    <org_study_id>11241</org_study_id>
    <secondary_id>H7T-MC-TACA</secondary_id>
    <nct_id>NCT00642174</nct_id>
  </id_info>
  <brief_title>Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)</brief_title>
  <acronym>OPTIMUS-3</acronym>
  <official_title>A Pharmacodynamic Comparison of Prasugrel (LY640315) Versus High Dose Clopidogrel in Subjects With Type 2 Diabetes Mellitus and Coronary Artery Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is designed as a phase 2 randomized, double-blind double dummy, active comparator
      controlled, two-period two-arm crossover study to enroll 40 patients across multiple centers.
      The study will compare platelet function following a prasugrel loading dose and 1 week of
      prasugrel maintenance therapy with high-dose clopidogrel loading dose and 1 week of high-dose
      clopidogrel maintenance therapy in patients with drug treated type 2 diabetes mellitus who
      have coronary artery disease. Various assays of platelet function will be used in this study.
      Platelet function will be studied using the following assays: Accumetrics VerifyNowTM P2Y12,
      Light Transmittance Aggregometry (LTA), Vasodilator-associated stimulated phosphoprotein
      (VASP), and Thromboelastography (TEG)-platelet mapping.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inhibition of Platelet Aggregation (IPA) 4 Hours After Loading Dose Assessed by Accumetrics VerifyNow™ P2Y12 Assay</measure>
    <time_frame>4 hours after loading dose</time_frame>
    <description>The inhibition of platelet aggregation 4 hours after the loading dose was administered was assessed using the Accumetrics VerifyNow™ P2Y12 assay. Percentage inhibition, as reported by VerifyNow™ P2Y12, was calculated from P2Y12 Reaction Unit (PRU) (rate and extent of adenosine diphosphate [ADP]-stimulated platelet aggregation) and BASE (estimate of baseline platelet reactivity independent of P2Y12 receptor inhibition [reference values]: rate and extent of Thrombin Receptor-Activated Peptide-stimulated platelet aggregation) values as follows: Percentage (%) inhibition = (1-PRU/BASE) x 100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inhibition of Platelet Aggregation at 1- and 24-Hours After Loading Dose (LD) and 24-Hours After Last Maintenance Dose (LMD) Assessed by Accumetrics VerifyNow™ P2Y12 Assay</measure>
    <time_frame>1 hour and 24 hours after the loading dose (LD) and 24 hours after the last maintenance dose (LMD)</time_frame>
    <description>Inhibition of platelet aggregation 1- and 24-hours after loading dose and 24-hours after last maintenance dose was administered was assessed using Accumetrics VerifyNow™ P2Y12 assay. Percentage inhibition, as reported by VerifyNow™ P2Y12, was calculated from PRU (rate and extent of ADP-stimulated platelet aggregation) and BASE (estimate of baseline platelet reactivity independent of P2Y12 receptor inhibition [reference values]: rate and extent of Thrombin Receptor-Activated Peptide-stimulated platelet aggregation) values as follows: Percentage (%) inhibition = (1-PRU/BASE) x 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Platelet Aggregation (MPA) as Assessed by Light Transmittance Aggregometry (LTA)</measure>
    <time_frame>Baseline, 1 Hour, 4 Hours, and 24 Hours after loading dose, and 24 Hours after last maintenance dose</time_frame>
    <description>Mean platelet aggregation (MPA) to 5 and 20 µM adenosine diphosphate (ADP) was assessed by light transmittance aggregometry (LTA). Platelet aggregation was monitored for a total of 7 minutes after addition of ADP. Maximum platelet aggregation was the maximal aggregation value achieved during the 7-minute observation period following addition of agonists.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Reactivity Index (PRI)</measure>
    <time_frame>Baseline, 1 Hour, 4 Hours, and 24 Hours after loading dose, and 24 Hours after last maintenance dose</time_frame>
    <description>Data from the Vasodilator-associated stimulated phosphoprotein assay were reported as the platelet reactivity index (PRI) which was calculated from corrected mean fluorescence intensity (cMFI) following incubation of platelets with either prostaglandin E1 (PGE1) alone or PGE1 plus ADP: Platelet Reactivity Index (%) = [1-(cMFI PGEI+ADP/cMFI PGEI)] x 100. Lower PRI values indicate greater platelet P2Y12 inhibition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inhibition of Platelet Function as Measured by Thromboelastography (TEG)-Platelet Mapping Maximum Amplitude - Adenosine Diphosphate</measure>
    <time_frame>Baseline, 1 Hour, 4 Hours, and 24 Hours after loading dose, and 24 Hours after last maintenance dose</time_frame>
    <description>Thromboelastography (TEG) platelet mapping (MP) maximum amplitude (MA) - Adenosine Diphosphate (ADP) millimeters (mm) at each time point. The TEG-MP MA measures strength of clot formation in whole blood. MA-ADP is the maximal amplitude resulting from fibrin and platelets not blocked by ADP-receptor inhibiting drugs. Fibrin strands in blood sample link a rotating sample cup with a stationary pin suspended by a torsion wire. The degree of platelet contribution to the MA through platelet-fibrin bonding directly influences the magnitude of pin movement and ultimately the amplitude of the tracing.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral prasugrel 60-mg loading dose, followed by 6 to 9 days of prasugrel 10-mg/day tablet maintenance dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral clopidogrel 600-mg loading dose, followed by 6 to 9 days of clopidogrel 150-mg/day tablet maintenance dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prasugrel</intervention_name>
    <description>Oral prasugrel 60-mg loading dose, followed by 6-9 days of oral prasugrel 10-mg/day tablet maintenance dose.</description>
    <arm_group_label>Prasugrel</arm_group_label>
    <other_name>LY640315</other_name>
    <other_name>Effient</other_name>
    <other_name>Efient</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Oral clopidogrel 600-mg loading dose, followed by 6-9 days of oral clopidogrel 150-mg/day tablet maintenance dose.</description>
    <arm_group_label>Clopidogrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 Diabetes Mellitus and on oral or parenteral hypoglycemic therapy for at least 1
             month.

          -  History of Coronary Artery Disease with or without other types of vascular disease
             (such as peripheral vascular disease).

          -  Taking Aspirin 75-325 mg/day for at least 1 week prior to randomization.

          -  Between the ages of 18-74 years old.

          -  If a woman of child bearing age, must not be pregnant and must agree to use reliable
             method of birth control during the duration of the study.

        Exclusion Criteria:

          -  Thienopyridine therapy within 30 days or have a defined need for thienopyridine
             treatment.

          -  Coronary Artery Bypass Graft (CABG) or Percutaneous Coronary Intervention (PCI) with
             no stent placed within 30 days.

          -  Planned coronary revascularization

          -  Hemoglobin A1c (HbA1c) &gt; or equal to 10 mg/dL within the last 3 months.

          -  Received fibrolytic therapy &lt;24 hours prior to randomization.

          -  Received non-fibrin-specific fibrinolytic therapy &lt;48 hours prior to randomization.

          -  At risk of bleeding.

          -  History of ischemic stroke, transient ischemic attack (TIA), intercranial neoplasm,
             arteriovenous malformation, or aneurysm.

          -  Body weight &lt;60 kilograms (kg).

          -  International Normalized Ratio (INR) &gt;1.5, platelet count &lt;100,000/mm3, or anemia
             (hemoglobin &lt;10 gm/dL) within 1 week of study entry.

          -  Are receiving or will receive oral anticoagulation or antiplatelet treatment therapy.

          -  Are being treated with daily non-steroidal anti-inflammatory drugs (NSAIDS).

          -  Are pregnant, breast-feeding or plan to become pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9am-5pm Eastern time (UTC/GMT-5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2008</study_first_submitted>
  <study_first_submitted_qc>March 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2008</study_first_posted>
  <results_first_submitted>January 18, 2010</results_first_submitted>
  <results_first_submitted_qc>January 18, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 12, 2010</results_first_posted>
  <last_update_submitted>February 19, 2010</last_update_submitted>
  <last_update_submitted_qc>February 19, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Prasugrel Then Clopidogrel</title>
          <description>Prasugrel: Oral prasugrel 60-mg loading dose, followed by 6 to 9 days of prasugrel 10-mg/day tablet maintenance dose. Clopidogrel: Oral clopidogrel 600-mg loading dose, followed by 6 to 9 days of clopidogrel 150-mg/day tablet maintenance dose.</description>
        </group>
        <group group_id="P2">
          <title>Clopidogrel Then Prasugrel</title>
          <description>Clopidogrel: Oral clopidogrel 600-mg loading dose, followed by 6 to 9 days of clopidogrel 150-mg/day tablet maintenance dose. Prasugrel: Oral prasugrel 60-mg loading dose, followed by 6 to 9 days of prasugrel 10-mg/day tablet maintenance dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1 - Initial Drug</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2 - Crossover Drug</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Prasugrel Then Clopidogrel</title>
          <description>Prasugrel: Oral prasugrel 60-mg loading dose, followed by 6 to 9 days of prasugrel 10-mg/day tablet maintenance dose. Clopidogrel: Oral clopidogrel 600-mg loading dose, followed by 6 to 9 days of clopidogrel 150-mg/day tablet maintenance dose.</description>
        </group>
        <group group_id="B2">
          <title>Clopidogrel Then Prasugrel</title>
          <description>Clopidogrel: Oral clopidogrel 600-mg loading dose, followed by 6 to 9 days of clopidogrel 150-mg/day tablet maintenance dose. Prasugrel: Oral prasugrel 60-mg loading dose, followed by 6 to 9 days of prasugrel 10-mg/day tablet maintenance dose.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.3" spread="9.43"/>
                    <measurement group_id="B2" value="62.4" spread="8.14"/>
                    <measurement group_id="B3" value="61.3" spread="8.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>East Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>West Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Inhibition of Platelet Aggregation (IPA) 4 Hours After Loading Dose Assessed by Accumetrics VerifyNow™ P2Y12 Assay</title>
        <description>The inhibition of platelet aggregation 4 hours after the loading dose was administered was assessed using the Accumetrics VerifyNow™ P2Y12 assay. Percentage inhibition, as reported by VerifyNow™ P2Y12, was calculated from P2Y12 Reaction Unit (PRU) (rate and extent of adenosine diphosphate [ADP]-stimulated platelet aggregation) and BASE (estimate of baseline platelet reactivity independent of P2Y12 receptor inhibition [reference values]: rate and extent of Thrombin Receptor-Activated Peptide-stimulated platelet aggregation) values as follows: Percentage (%) inhibition = (1-PRU/BASE) x 100.</description>
        <time_frame>4 hours after loading dose</time_frame>
        <population>Pharmacodynamic Population, which included all randomized participants who had blood draws for IPA at 4 hours, who met compliance criteria, and who had last dose of study drug prior to the blood draw for IPA.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel</title>
            <description>Prasugrel: Oral prasugrel 60-mg loading dose, followed by 6 to 9 days of prasugrel 10-mg/day tablet maintenance dose.</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel: Oral clopidogrel 600-mg loading dose, followed by 6 to 9 days of clopidogrel 150-mg/day tablet maintenance dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Inhibition of Platelet Aggregation (IPA) 4 Hours After Loading Dose Assessed by Accumetrics VerifyNow™ P2Y12 Assay</title>
          <description>The inhibition of platelet aggregation 4 hours after the loading dose was administered was assessed using the Accumetrics VerifyNow™ P2Y12 assay. Percentage inhibition, as reported by VerifyNow™ P2Y12, was calculated from P2Y12 Reaction Unit (PRU) (rate and extent of adenosine diphosphate [ADP]-stimulated platelet aggregation) and BASE (estimate of baseline platelet reactivity independent of P2Y12 receptor inhibition [reference values]: rate and extent of Thrombin Receptor-Activated Peptide-stimulated platelet aggregation) values as follows: Percentage (%) inhibition = (1-PRU/BASE) x 100.</description>
          <population>Pharmacodynamic Population, which included all randomized participants who had blood draws for IPA at 4 hours, who met compliance criteria, and who had last dose of study drug prior to the blood draw for IPA.</population>
          <units>percent inhibition</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="10.23" lower_limit="5.55" upper_limit="13.18"/>
                    <measurement group_id="O2" value="9.3" spread="11.46" lower_limit="5.55" upper_limit="13.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Hours After Loading Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.3" spread="9.40" lower_limit="82.96" upper_limit="95.60"/>
                    <measurement group_id="O2" value="27.7" spread="23.82" lower_limit="21.49" upper_limit="33.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there is no difference between prasugrel and clopidogrel in IPA assessed by Accumetrics VerifyNow™ P2Y12 4 hours after administration of loading dose. Assuming 90% power, 2-sided alpha of 0.05, and a 17.5% difference in IPA between treatment groups with a standard deviation of 20, a total of 15 completed subjects per sequence group (i.e., 15 subject who receive prasugrel first, then clopidogrel; and 15 subjects who receive clopidogrel first, then prasugrel) was determined.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is for 4 Hours After Loading Dose.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Linear mixed model with treatment, sequence and treatment by sequence (i.e. period) as fixed effects and subject as random effect.</method_desc>
            <param_type>Least Squares Mean Difference (Net)</param_type>
            <param_value>61.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>53.83</ci_lower_limit>
            <ci_upper_limit>69.31</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Prasugrel minus Clopidogrel.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inhibition of Platelet Aggregation at 1- and 24-Hours After Loading Dose (LD) and 24-Hours After Last Maintenance Dose (LMD) Assessed by Accumetrics VerifyNow™ P2Y12 Assay</title>
        <description>Inhibition of platelet aggregation 1- and 24-hours after loading dose and 24-hours after last maintenance dose was administered was assessed using Accumetrics VerifyNow™ P2Y12 assay. Percentage inhibition, as reported by VerifyNow™ P2Y12, was calculated from PRU (rate and extent of ADP-stimulated platelet aggregation) and BASE (estimate of baseline platelet reactivity independent of P2Y12 receptor inhibition [reference values]: rate and extent of Thrombin Receptor-Activated Peptide-stimulated platelet aggregation) values as follows: Percentage (%) inhibition = (1-PRU/BASE) x 100.</description>
        <time_frame>1 hour and 24 hours after the loading dose (LD) and 24 hours after the last maintenance dose (LMD)</time_frame>
        <population>Pharmacodynamic Population, which included all randomized participants who had blood draws for IPA, who met compliance criteria, and who had last dose of study drug prior to the blood draw for IPA.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel</title>
            <description>Prasugrel: Oral prasugrel 60-mg loading dose, followed by 6 to 9 days of prasugrel 10-mg/day tablet maintenance dose.</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel: Oral clopidogrel 600-mg loading dose, followed by 6 to 9 days of clopidogrel 150-mg/day tablet maintenance dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Inhibition of Platelet Aggregation at 1- and 24-Hours After Loading Dose (LD) and 24-Hours After Last Maintenance Dose (LMD) Assessed by Accumetrics VerifyNow™ P2Y12 Assay</title>
          <description>Inhibition of platelet aggregation 1- and 24-hours after loading dose and 24-hours after last maintenance dose was administered was assessed using Accumetrics VerifyNow™ P2Y12 assay. Percentage inhibition, as reported by VerifyNow™ P2Y12, was calculated from PRU (rate and extent of ADP-stimulated platelet aggregation) and BASE (estimate of baseline platelet reactivity independent of P2Y12 receptor inhibition [reference values]: rate and extent of Thrombin Receptor-Activated Peptide-stimulated platelet aggregation) values as follows: Percentage (%) inhibition = (1-PRU/BASE) x 100.</description>
          <population>Pharmacodynamic Population, which included all randomized participants who had blood draws for IPA, who met compliance criteria, and who had last dose of study drug prior to the blood draw for IPA.</population>
          <units>percent inhibition</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 Hour After Loading Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.9" lower_limit="41.17" upper_limit="58.60"/>
                    <measurement group_id="O2" value="13.4" lower_limit="4.92" upper_limit="21.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hours After Loading Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.1" lower_limit="80.64" upper_limit="93.66"/>
                    <measurement group_id="O2" value="29.3" lower_limit="22.87" upper_limit="35.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hours After Last Maintenance Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.8" lower_limit="55.70" upper_limit="67.91"/>
                    <measurement group_id="O2" value="44.2" lower_limit="38.05" upper_limit="50.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there was no difference between prasugrel and clopidogrel in IPA assessed by Accumetrics VerifyNow™ P2Y12 1 hour after administration of the loading dose.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for 1 Hour After Loading Dose. A priori threshold for statistical significance was set at p=0.05 level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Linear mixed model with treatment, sequence and treatment by sequence (ie. period) as fixed effects and subject as random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>36.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>27.43</ci_lower_limit>
            <ci_upper_limit>45.52</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Prasugrel minus Clopidogrel.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there was no difference between prasugrel and clopidogrel in IPA assessed by Accumetrics VerifyNow™ P2Y12 24 hours after administration of the loading dose.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for 24 Hour After Loading Dose. A priori threshold for statistical significance was set at p=0.05 level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Linear mixed model with treatment, sequence and treatment by sequence (ie. period) as fixed effects and subject as random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>57.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>49.56</ci_lower_limit>
            <ci_upper_limit>66.19</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Prasugrel minus Clopidogrel.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: there was no difference between prasugrel and clopidogrel in IPA assessed by Accumetrics VerifyNow™ P2Y12 24 hours post-Last Maintenance Dose (LMD).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for 24 Hours After Last Maintenance Dose. A priori threshold for statistical significance was set at p=0.05 level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Linear mixed model with treatment, sequence and treatment by sequence (ie. period) as fixed effects and subject as random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>17.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>10.27</ci_lower_limit>
            <ci_upper_limit>25.04</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Prasugrel minus Clopidogrel.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Platelet Aggregation (MPA) as Assessed by Light Transmittance Aggregometry (LTA)</title>
        <description>Mean platelet aggregation (MPA) to 5 and 20 µM adenosine diphosphate (ADP) was assessed by light transmittance aggregometry (LTA). Platelet aggregation was monitored for a total of 7 minutes after addition of ADP. Maximum platelet aggregation was the maximal aggregation value achieved during the 7-minute observation period following addition of agonists.</description>
        <time_frame>Baseline, 1 Hour, 4 Hours, and 24 Hours after loading dose, and 24 Hours after last maintenance dose</time_frame>
        <population>Pharmacodynamic Population, which included all randomized participants who had blood draws for MPA, who met compliance criteria, and who had last dose of study drug prior to the blood draw for MPA.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel</title>
            <description>Prasugrel: Oral prasugrel 60-mg loading dose, followed by 6 to 9 days of prasugrel 10-mg/day tablet maintenance dose.</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel: Oral clopidogrel 600-mg loading dose, followed by 6 to 9 days of clopidogrel 150-mg/day tablet maintenance dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Platelet Aggregation (MPA) as Assessed by Light Transmittance Aggregometry (LTA)</title>
          <description>Mean platelet aggregation (MPA) to 5 and 20 µM adenosine diphosphate (ADP) was assessed by light transmittance aggregometry (LTA). Platelet aggregation was monitored for a total of 7 minutes after addition of ADP. Maximum platelet aggregation was the maximal aggregation value achieved during the 7-minute observation period following addition of agonists.</description>
          <population>Pharmacodynamic Population, which included all randomized participants who had blood draws for MPA, who met compliance criteria, and who had last dose of study drug prior to the blood draw for MPA.</population>
          <units>percent platelet aggregation</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (5 μM ADP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.9" lower_limit="61.62" upper_limit="68.14"/>
                    <measurement group_id="O2" value="65.7" lower_limit="62.49" upper_limit="68.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Hour After Loading Dose (5 μM ADP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.7" lower_limit="28.44" upper_limit="39.03"/>
                    <measurement group_id="O2" value="56.7" lower_limit="51.69" upper_limit="61.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Hours After Loading Dose (5 μM ADP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" lower_limit="13.41" upper_limit="22.51"/>
                    <measurement group_id="O2" value="44.6" lower_limit="40.11" upper_limit="49.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hours After Loading Dose (5 μM ADP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3" lower_limit="17.78" upper_limit="26.89"/>
                    <measurement group_id="O2" value="45.6" lower_limit="41.20" upper_limit="50.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hours After Last Maintenance Dose (5 μM ADP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.6" lower_limit="25.20" upper_limit="34.08"/>
                    <measurement group_id="O2" value="38.3" lower_limit="33.93" upper_limit="42.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (20 μM ADP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.1" lower_limit="73.74" upper_limit="80.43"/>
                    <measurement group_id="O2" value="76.9" lower_limit="73.54" upper_limit="80.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Hour After Loading Dose (20 μM ADP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7" lower_limit="38.54" upper_limit="50.77"/>
                    <measurement group_id="O2" value="69.8" lower_limit="64.05" upper_limit="75.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Hours After Loading Dose (20 μM ADP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4" lower_limit="16.99" upper_limit="27.81"/>
                    <measurement group_id="O2" value="57.5" lower_limit="52.16" upper_limit="62.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hours After Loading Dose (20 μM ADP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.4" lower_limit="22.23" upper_limit="32.67"/>
                    <measurement group_id="O2" value="58.4" lower_limit="53.39" upper_limit="63.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hours After Last Maintenance Dose (20 μM ADP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.3" lower_limit="32.97" upper_limit="43.64"/>
                    <measurement group_id="O2" value="50.7" lower_limit="45.42" upper_limit="55.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference between prasugrel and clopidogrel in MPA assessed by Light Transmittance Aggregometry (LTA).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5466</p_value>
            <p_value_desc>P-value for Baseline (5 uM ADP). A priori threshold for statistical significance was set at p=0.05 level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Linear mixed model with treatment, sequence and treatment by sequence (ie. period) as fixed effects and subject as random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.66</ci_lower_limit>
            <ci_upper_limit>1.97</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Prasugrel minus Clopidogrel.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference between prasugrel and clopidogrel in MPA assessed by Light Transmittance Aggregometry (LTA).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for 1 After Post Loading Dose (5 uM ADP). A priori threshold for statistical significance was set at p=0.05 level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Linear mixed model with treatment, sequence and treatment by sequence (ie. period) as fixed effects and subject as random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-23.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-28.45</ci_lower_limit>
            <ci_upper_limit>-17.55</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Prasugrel minus Clopidogrel.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference between prasugrel and clopidogrel in MPA assessed by Light Transmittance Aggregometry (LTA).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for 4 Hour After Loading Dose (5 uM ADP). A priori threshold for statisitical significance was set at p=0.05 level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Linear mixed model with treatment, sequence and treatment by sequence (ie. period) as fixed effects and subject as random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-26.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-31.18</ci_lower_limit>
            <ci_upper_limit>-22.02</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Prasugrel minus Clopidogrel.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference between prasugrel and clopidogrel in MPA assessed by Light Transmittance Aggregometry (LTA).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for 24 Hour After Loading Dose (5 uM ADP). A priori threshold for statistical significance was set at p=0.05 level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Linear mixed model with treatment, sequence and treatment by sequence (ie. period) as fixed effects and subject as random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-23.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-27.42</ci_lower_limit>
            <ci_upper_limit>-19.17</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Prasugrel minus Clopidogrel.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference between prasugrel and clopidogrel in MPA assessed by Light Transmittance Aggregometry (LTA).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <p_value_desc>P-value for 24 Hour After Last Maintenance Dose (5 uM ADP). A priori threshold for statistical significance was set at p=0.05 level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Linear mixed model with treatment, sequence and treatment by sequence (ie. period) as fixed effects and subject as random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-8.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-12.78</ci_lower_limit>
            <ci_upper_limit>-4.58</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Prasugrel minus Clopidogrel.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference between prasugrel and clopidogrel in MPA assessed by Light Transmittance Aggregometry (LTA).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8779</p_value>
            <p_value_desc>P-value for Baseline (20 uM ADP). A priori threshold for statistical significance was set at p=0.05 level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Linear mixed model with treatment, sequence and treatment by sequence (ie. period) as fixed effects and subject as random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.80</ci_lower_limit>
            <ci_upper_limit>3.26</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Prasugrel minus Clopidogrel.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference between prasugrel and clopidogrel in MPA assessed by Light Transmittance Aggregometry (LTA).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for 1 Hour After Loading Dose (20 uM ADP). A priori threshold for statistical significance was set at p=0.05 level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Linear mixed model with treatment, sequence and treatment by sequence (ie. period) as fixed effects and subject as random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-25.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-32.43</ci_lower_limit>
            <ci_upper_limit>-17.87</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Prasugrel minus Clopidogrel.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference between prasugrel and clopidogrel in MPA assessed by Light Transmittance Aggregometry (LTA).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for 4 Hour After Loading Dose (20 uM ADP). A priori threshold for statistical significance was set at p=0.05 level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Linear mixed model with treatment, sequence and treatment by sequence (ie. period) as fixed effects and subject as random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-35.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-40.32</ci_lower_limit>
            <ci_upper_limit>-29.78</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Prasugrel minus Clopidogrel.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference between prasugrel and clopidogrel in MPA assessed by Light Transmittance Aggregometry (LTA).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for 24 Hour After Loading Dose (20 uM ADP). A priori threshold for statistical significance was set at p=0.05 level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Linear mixed model with treatment, sequence and treatment by sequence (ie. period) as fixed effects and subject as random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-31.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-36.32</ci_lower_limit>
            <ci_upper_limit>-25.66</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Prasugrel minus Clopidogrel.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference between prasugrel and clopidogrel in MPA assessed by Light Transmittance Aggregometry (LTA).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for 24 Hour After Last Maintenance Dose (20 uM ADP). A priori threshold for statistical significance was set at p=0.05 level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Linear mixed model with treatment, sequence and treatment by sequence (ie. period) as fixed effects and subject as random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-12.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-17.19</ci_lower_limit>
            <ci_upper_limit>-7.58</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Prasugrel minus Clopidogrel.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Reactivity Index (PRI)</title>
        <description>Data from the Vasodilator-associated stimulated phosphoprotein assay were reported as the platelet reactivity index (PRI) which was calculated from corrected mean fluorescence intensity (cMFI) following incubation of platelets with either prostaglandin E1 (PGE1) alone or PGE1 plus ADP: Platelet Reactivity Index (%) = [1-(cMFI PGEI+ADP/cMFI PGEI)] x 100. Lower PRI values indicate greater platelet P2Y12 inhibition.</description>
        <time_frame>Baseline, 1 Hour, 4 Hours, and 24 Hours after loading dose, and 24 Hours after last maintenance dose</time_frame>
        <population>Pharmacodynamic Population, which included all randomized participants who had blood draws for Vasodilator-Associated Stimulated Phosphoprotein (VASP), who met compliance criteria, and who had last dose of study drug prior to the blood draw for inhibition of platelet function as assessed by VASP.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel</title>
            <description>Prasugrel: Oral prasugrel 60-mg loading dose, followed by 6 to 9 days of prasugrel 10-mg/day tablet maintenance dose.</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel: Oral clopidogrel 600-mg loading dose, followed by 6 to 9 days of clopidogrel 150-mg/day tablet maintenance dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Reactivity Index (PRI)</title>
          <description>Data from the Vasodilator-associated stimulated phosphoprotein assay were reported as the platelet reactivity index (PRI) which was calculated from corrected mean fluorescence intensity (cMFI) following incubation of platelets with either prostaglandin E1 (PGE1) alone or PGE1 plus ADP: Platelet Reactivity Index (%) = [1-(cMFI PGEI+ADP/cMFI PGEI)] x 100. Lower PRI values indicate greater platelet P2Y12 inhibition.</description>
          <population>Pharmacodynamic Population, which included all randomized participants who had blood draws for Vasodilator-Associated Stimulated Phosphoprotein (VASP), who met compliance criteria, and who had last dose of study drug prior to the blood draw for inhibition of platelet function as assessed by VASP.</population>
          <units>percent inhibition</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.5" lower_limit="78.76" upper_limit="88.31"/>
                    <measurement group_id="O2" value="80.6" lower_limit="75.92" upper_limit="85.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Hour After Loading Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0" lower_limit="32.14" upper_limit="47.80"/>
                    <measurement group_id="O2" value="76.2" lower_limit="68.48" upper_limit="83.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Hours After Loading Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" lower_limit="7.73" upper_limit="21.35"/>
                    <measurement group_id="O2" value="67.5" lower_limit="60.79" upper_limit="74.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hours After Loading Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" lower_limit="8.33" upper_limit="22.99"/>
                    <measurement group_id="O2" value="58.5" lower_limit="51.30" upper_limit="65.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hours After Last Maintenance Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.4" lower_limit="20.82" upper_limit="34.03"/>
                    <measurement group_id="O2" value="42.3" lower_limit="35.72" upper_limit="48.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference between prasugrel and clopidogrel in Inhibition of Platelet Function as assessed by VASP.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3692</p_value>
            <p_value_desc>P-value for Baseline. A priori threshold for statistical significance was set at p=0.05 level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Linear mixed model with treatment, sequence and treatment by sequence (ie. period) as fixed effects and subject as random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.60</ci_lower_limit>
            <ci_upper_limit>9.44</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Prasugrel minus Clopidogrel.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference between prasugrel and clopidogrel in Inhibition of Platelet Function as assessed by VASP.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for 1 Hour After Loading Dose. A priori threshold for statistical significance was set at p=0.05 level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Linear mixed model with treatment, sequence and treatment by sequence (ie. period) as fixed effects and subject as random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-36.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-47.43</ci_lower_limit>
            <ci_upper_limit>-24.98</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Prasugrel minus Clopidogrel.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference between prasugrel and clopidogrel in Inhibition of Platelet Function as assessed by VASP.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for 4 Hours After Loading Dose. A priori threshold for statistical significance was set at p=0.05 level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Linear mixed model with treatment, sequence and treatment by sequence (ie. period) as fixed effects and subject as random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-53.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-61.89</ci_lower_limit>
            <ci_upper_limit>-44.02</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Prasugrel minus Clopidogrel.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference between prasugrel and clopidogrel in Inhibition of Platelet Function as assessed by VASP.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for 24 Hours After Loading Dose. A priori threshold for statistical significance was set at p=0.05 level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Linear mixed model with treatment, sequence and treatment by sequence (ie. period) as fixed effects and subject as random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-42.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-50.03</ci_lower_limit>
            <ci_upper_limit>-35.55</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Prasugrel minus Clopidogrel.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that there was no difference between prasugrel and clopidogrel in Inhibition of Platelet Function as assessed by VASP.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <p_value_desc>P-value for 24 Hours After Last Maintenance Dose. A priori threshold for statistical significance was set to p=0.05 level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Linear mixed model with treatment, sequence and treatment by sequence (ie. period) as fixed effects and subject as random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-14.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-23.42</ci_lower_limit>
            <ci_upper_limit>-6.37</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Prasugrel minus Clopidogrel.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inhibition of Platelet Function as Measured by Thromboelastography (TEG)-Platelet Mapping Maximum Amplitude - Adenosine Diphosphate</title>
        <description>Thromboelastography (TEG) platelet mapping (MP) maximum amplitude (MA) – Adenosine Diphosphate (ADP) millimeters (mm) at each time point. The TEG-MP MA measures strength of clot formation in whole blood. MA-ADP is the maximal amplitude resulting from fibrin and platelets not blocked by ADP-receptor inhibiting drugs. Fibrin strands in blood sample link a rotating sample cup with a stationary pin suspended by a torsion wire. The degree of platelet contribution to the MA through platelet-fibrin bonding directly influences the magnitude of pin movement and ultimately the amplitude of the tracing.</description>
        <time_frame>Baseline, 1 Hour, 4 Hours, and 24 Hours after loading dose, and 24 Hours after last maintenance dose</time_frame>
        <population>Pharmacodynamic Population, which included all randomized participants who had blood draws for Inhibition of Platelet Function (IPF) as measured by Thromboelastography (TEG)-Platelet Mapping Maximum Amplitude - Adenosine Diphosphate (ADP), who met compliance criteria, and who had last dose of study drug prior to blood draw for IPF.</population>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel</title>
            <description>Prasugrel: Oral prasugrel 60-mg loading dose, followed by 6 to 9 days of prasugrel 10-mg/day tablet maintenance dose.</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel</title>
            <description>Clopidogrel: Oral clopidogrel 600-mg loading dose, followed by 6 to 9 days of clopidogrel 150-mg/day tablet maintenance dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Inhibition of Platelet Function as Measured by Thromboelastography (TEG)-Platelet Mapping Maximum Amplitude - Adenosine Diphosphate</title>
          <description>Thromboelastography (TEG) platelet mapping (MP) maximum amplitude (MA) – Adenosine Diphosphate (ADP) millimeters (mm) at each time point. The TEG-MP MA measures strength of clot formation in whole blood. MA-ADP is the maximal amplitude resulting from fibrin and platelets not blocked by ADP-receptor inhibiting drugs. Fibrin strands in blood sample link a rotating sample cup with a stationary pin suspended by a torsion wire. The degree of platelet contribution to the MA through platelet-fibrin bonding directly influences the magnitude of pin movement and ultimately the amplitude of the tracing.</description>
          <population>Pharmacodynamic Population, which included all randomized participants who had blood draws for Inhibition of Platelet Function (IPF) as measured by Thromboelastography (TEG)-Platelet Mapping Maximum Amplitude - Adenosine Diphosphate (ADP), who met compliance criteria, and who had last dose of study drug prior to blood draw for IPF.</population>
          <units>millimeters (mm)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.8" lower_limit="52.37" upper_limit="61.21"/>
                    <measurement group_id="O2" value="58.1" lower_limit="53.70" upper_limit="62.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Hour After Loading Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5" lower_limit="33.42" upper_limit="43.63"/>
                    <measurement group_id="O2" value="54.8" lower_limit="49.84" upper_limit="59.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Hours After Loading Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2" lower_limit="18.80" upper_limit="29.6"/>
                    <measurement group_id="O2" value="48.1" lower_limit="42.84" upper_limit="53.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hours After Loading Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.3" lower_limit="24.56" upper_limit="34.01"/>
                    <measurement group_id="O2" value="49.2" lower_limit="44.61" upper_limit="53.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hours After Last Maintenance Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.2" lower_limit="38.77" upper_limit="49.62"/>
                    <measurement group_id="O2" value="46.8" lower_limit="41.37" upper_limit="52.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: no difference between prasugrel and clopidogrel in Inhibition of Platelet Function as measured by Thromboelastography (TEG)-Platelet Mapping Maximum Amplitude - Adenosine Diphosphate (ADP).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5238</p_value>
            <p_value_desc>P-value for Baseline. A priori threshold for statistical significance was set at p=0.05 level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Linear mixed model with treatment, sequence and treatment by sequence (ie. period) as fixed effects and subject as random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.35</ci_lower_limit>
            <ci_upper_limit>2.78</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Prasugrel minus Clopidogrel.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: no difference between prasugrel and clopidogrel in Inhibition of Platelet Function as measured by Thromboelastography (TEG)-Platelet Mapping Maximum Amplitude - Adenosine Diphosphate (ADP).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for 1 Hour After Loading Dose. A priori threshold for statistical significance was set at p=0.05 level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Linear mixed model with treatment, sequence and treatment by sequence (ie. period) as fixed effects and subject as random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-16.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-21.15</ci_lower_limit>
            <ci_upper_limit>-11.33</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Prasugrel minus Clopidogrel.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: no difference between prasugrel and clopidogrel in Inhibition of Platelet Function as measured by Thromboelastography (TEG)-Platelet Mapping Maximum Amplitude - Adenosine Diphosphate (ADP).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for 4 Hours After Loading Dose. A priori threshold for statistical significance was set at p=0.05 level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Linear mixed model with treatment, sequence and treatment by sequence (ie. period) as fixed effects and subject as random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-23.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-29.67</ci_lower_limit>
            <ci_upper_limit>-18.11</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Prasugrel minus Clopidogrel.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: no difference between prasugrel and clopidogrel in Inhibition of Platelet Function as measured by Thromboelastography (TEG)-Platelet Mapping Maximum Amplitude - Adenosine Diphosphate (ADP).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value for 24 Hours After Loading Dose. A priori threshold for statistical significance was set at p=0.05 level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Linear mixed model with treatment, sequence and treatment by sequence (ie. period) as fixed effects and subject as random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-19.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-24.97</ci_lower_limit>
            <ci_upper_limit>-14.90</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Prasugrel minus Clopidogrel.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: no difference between prasugrel and clopidogrel in Inhibition of Platelet Function as measured by Thromboelastography (TEG)-Platelet Mapping Maximum Amplitude - Adenosine Diphosphate (ADP).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3725</p_value>
            <p_value_desc>P-value for 24 Hours After Last Maintenance Dose. A priori threshold for statistical significance was set at p=0.05 level.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Linear mixed model with treatment, sequence and treatment by sequence (ie. period) as fixed effects and subject as random effect.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-8.46</ci_lower_limit>
            <ci_upper_limit>3.26</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Prasugrel minus Clopidogrel.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Prasugrel</title>
          <description>Prasugrel: Oral prasugrel 60-mg loading dose, followed by 6 to 9 days of prasugrel 10-mg/day tablet maintenance dose.</description>
        </group>
        <group group_id="E2">
          <title>Clopidogrel</title>
          <description>Clopidogrel: Oral clopidogrel 600-mg loading dose, followed by 6 to 9 days of clopidogrel 150-mg/day tablet maintenance dose.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Vessel puncture site haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Wart excision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

